期刊文献+

特应性皮炎患者血清白细胞介素-33水平及其临床意义

下载PDF
导出
摘要 特应性皮炎(AD)是一种以皮肤干燥、湿疹样皮损和明显瘙痒为主要临床特征的慢性过敏性皮肤病^([1])。近年来,AD的发病率逐步上升,影响着全球约20%儿童及3%成人^([2-3])。有研究表明免疫失调是AD发病的关键环节,其中辅助性T细胞(Th)1/Th2分化失衡引起细胞因子分泌异常在AD发生和发展中起着重要作用^([4])。白细胞介素(IL)-33是IL-1细胞因子家族成员,IL-33与其受体结合后激活Th2及肥大细胞等,产生IL-4及IL-5等细胞因子,从而促进Th2型细胞因子介导的免疫反应^([5])。多项研究发现IL-33在AD患者皮损中表达水平升高^([6-7])。此外,AD患者血清可在体外抑制角质形成细胞β-防御素2的表达,从而减弱皮肤抗炎能力,进一步提示IL-33在AD发生和发展中发挥重要作用^([8])本研究通过检测AD患者血清IL-33水平,并分析其与患者临床资料的相关性,探讨IL-33在AD患者血清中的表达及其临床意义,现将结果报告如下。
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2023年第6期332-335,共4页 Journal of Clinical Dermatology
  • 相关文献

参考文献5

二级参考文献64

  • 1Akdis CA, Akdis M, Biebcr T, Bindslev-Jcnsen C, Boguniewicz M, Eigemnann P, el al Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical hnmunologyAmerican Academy of Allergy, Asthma and lmmunologyPRACTALL Consensus Report. Allergy 2006;61:969-87. dot: 10,111 Ij. 1398-9995.2006.01153.x.
  • 2Darsow U, Wollenbcrg A, Simon D, TaTeb A, Werfcl T, Oranje A, et al. ETFADEADV eczema task force 2009 position paper on diagnosis and treatment ot" atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-28. dot: 10.11 I 1j. 1468-3083.2009.03415. x.
  • 3Hanifin .IM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis D J, el ell. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD) American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dcrmatol 2004;50:391-404. dot: 10.1016j. jaad.2003.08.003.
  • 4Biebcr 11 Atopic dermatilis. N Engl d Med 2008;358:1483-94. dot: 10.1056N EJ Mra07408.
  • 5I. ,Iohansson SG, Hourihane JO, Bousquet J, BruijnzeeI-Koomcn C, Dreborg S, Haahtela T, el al. A revised nomenclature lbr allergy. An EAACI position statement from the EAACI nomenclature task fbrce. Allergy 2001;56:813-24. dot: 10.1034j.1398-9995.2001. t01 - 1-00001 .x.
  • 6Ring J, Alomar A, B ieber T, Deleuran M, Fink-Wagncr A, Gelmetti C, et al. Guidclines for treatment of atopic eczema (atopic dermatitis) part 1. J Eur Acad Dermatol Venereol 2012;26:1045-60. dot: 10. I 1 I 1 i-1468-3083.2012.04635.x.
  • 7Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Parl II. J Eur Acad Dermatol Venereol 2012;26:1176-93. dot: 10.1111j. 1468-3083.2012.04636.x.
  • 8Hotl]an S, Epplen JT. The genetics of atopic dermatitis: Recent findings and future options. J Mol Med (Berl) 2005;83:682-92. dot: 10. 1007s00 } 09-005-0672-2.
  • 9Jencrowicz D, Silny W, Danczak-Pazdrowska A, Polanska A, Osmola-Mankowska A, Olek-Hrab K. Environmental thctors and allergic diseases. Ann Agric Environ Med 2012; 19:475-81.
  • 10Proksch E, F61sier-Holst R, Jeusen JM. Skin barrier tunctiou, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006;43:159-69. doi: 10. [ 016j.jdennsci.2006.06.003.

共引文献114

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部